MTOR and breast carcinoma: To overcome these resistance issues Rodrik-outmezguine and colleagues have generated rapamycin-resistant breast carcinoma cell lines that carry two mutations in the mTOR FRB domain (mTOR A2034V and mTOR F2108L).148 They also generated the AZD8055-resistant colony that bears mutations in the hyperactive kinase domain.